What Can We Learn from Epidemiological Studies in Inflammatory Bowel Disease?

Digestive Diseases

Volumn 35, Issue 1-2, 2017, Pages 69-73

  Duricova, Dana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Biological therapy; Colorectal cancer; Immunosuppressive therapy; Inflammatory bowel disease; Surgery

Indexed keywords

IMMUNOMODULATING AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

CANCER RISK; CLINICAL STUDY; COLON RESECTION; COLORECTAL CANCER; CROHN DISEASE; DISEASE DURATION; HAZARD RATIO; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE SURGERY; META ANALYSIS (TOPIC); POPULATION BASED CASE CONTROL STUDY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ULCERATIVE COLITIS; ADULT; AGED; BIOLOGICAL THERAPY; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; COMPLICATION; EPIDEMIOLOGY; FEMALE; MALE; MIDDLE AGED; RISK; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; BIOLOGICAL THERAPY; COLECTOMY; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RISK;

EID: 85011660597     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000449086     Document Type: Review

References (27)

1. Burisch J, Jess T, Martinato M, Lakatos PL; ECCO-EpiCom: The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013; 7: 322-337.
2. Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B; Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD): Hospitalisations and surgery in Crohn's disease. Gut 2012; 61: 622-629.
3. Chatu S, Saxena S, Subramanian V, Curcin V, Yadegarfar G, Gunn L, et al: The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn's disease: national UK population-based study 1989-2010. Am J Gastroenterol 2014; 109: 409-416.
4. Rungoe C, Langholz E, Andersson M, Basit S, Nielsen NM, Wohlfahrt J, et al: Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014; 63: 1607-1616.
5. Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM, et al: Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013; 145: 996-1006.
6. Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, et al: Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006; 55: 510-518.
7. Frolkis AD, Lipton DS, Fiest KM, Negron ME, Dykeman J, deBruyn J, et al: Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol 2014; 109: 1739-1748.
8. Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, et al: Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007; 132: 507-515.
9. Jeuring SF, Bours PH, Zeegers MP, Ambergen TW, van den Heuvel TR, Romberg-Camps MJ, et al: Disease outcome of ulcerative colitis in an era of changing treatment strategies: results from the Dutch population-based IBDSL cohort. J Crohns Colitis 2015; 9: 837-845.
10. Kaplan GG, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, et al: Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012; 107: 1879-1887.
11. Samuel S, Ingle SB, Dhillon S, Yadav S, Harmsen WS, Zinsmeister AR, et al: Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 2013; 19: 1858-1866.
12. Chhaya V, Saxena S, Cecil E, Chatu S, Subramanian V, Curcin V, et al: The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009. Aliment Pharmacol Ther 2015; 41: 87-98.
13. Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, et al: Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012; 107: 579-588.
14. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB: Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-1206.
15. Kariyawasam VC, Selinger CP, Katelaris PH, Jones DB, McDonald C, Barr G, et al: Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease. Inflamm Bowel Dis 2014; 20: 1382-1390.
16. Chatu S, Subramanian V, Saxena S, Pollok RC: The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 23-34; quiz 35.
17. Reich KM, Chang HJ, Rezaie A, Wang H, Goodman KJ, Kaplan GG, et al: The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther 2014; 40: 629-638.
18. Moore SE, McGrail KM, Peterson S, Raval MJ, Karimuddin AA, Phang PT, et al: Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. Dis Colon Rectum 2014; 57: 83-90.
19. Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535.
20. Jess T, Rungoe C, Peyrin-Biroulet L: Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645.
21. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B: Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013; 19: 789-799.
22. Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M: Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-381.e1; quiz e13-e14.
23. van den Heuvel T, Jeuring S, Wassink M, Glorie C, Oostenburg L, Romberg-Camps M, et al: Decreased colorectal cancer risk in Dutch ulcerative colitis patients: results from the population based IBD-SL cohort. J Crohns Colitis 2014; 8(suppl 1):S61-S62.
24. Castano-Milla C, Chaparro M, Gisbert JP: Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 2014; 39: 645-659.
25. Sebastian S, Hernandez V, Myrelid P, Kariv R, Tsianos E, Toruner M, et al: Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis 2014; 8: 5-18.
26. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI: Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100: 2724-2729.
27. Canavan C, Abrams KR, Mayberry J: Metaanalysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23: 1097-1104.